ArticleInsights into imaging2026
Deep learning in differentiating the colorectal cancer combined with hepatic enhancing nodules: liver metastases vs hemangiomas.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesTo assess a deep learning (DL) model using portal-venous phase CT for discriminating colorectal cancer liver metastasis (CRLMs) and hemangiomas (HMs). MATERIALS AND
methodsColorectal cancer (CRC) patients diagnosed with CRLMs or HMs at two medical centers from January 2018 and April 2024 were retrospectively included. Lesions were automatically segmented using TotalSegmentator. DL models, DenseNet-201 and ResNet-152, were trained to classify CRLMs and HMs. Their performance, measured by AUC, was evaluated on validation and test sets. Subgroup analyses were conducted for lesions ≤ 10 mm (subcentimeter) and 10-30 mm. Radiologists' diagnostic performance with and without DL assistance was compared using a multi-reader multi-case analysis.
results534 CRLMs (134 CRC-patients; median, 60 years) and 262 HMs (154 CRC-patients; median, 62 years) were divided into the training, validation and test set. The Dice coefficients of TotalSegmentor for automatically segmenting subcentimeter and 10-30 mm lesions were 0.692 ± 0.099 and 0.861 ± 0.033, respectively (p < 0.01). ResNet-152 model achieved AUCs of 0.875 (95% CI: 0.838-0.912), 0.858 (95% CI: 0.781-0.935), 0.776 (95% CI: 0.703-0.848) for classifying CRLMs and HMs on the training, validation, and test sets, respectively. The AUCs for distinguishing between 10-30 mm CRLMs and HMs improved from 0.851 (95% CI: 0.821-0.880) to 0.879 (95% CI: 0.853-0.906) with DL assistance compared to without (p = 0.015). For subcentimeter CRLMs and HMs, the AUCs for the radiologists and the DL-assisted diagnosis were 0.742 (95% CI: 0.669-0.814) and 0.763 (95% CI: 0.681-0.845), respectively (p = 0.558).
conclusionDL can assist radiologists in distinguishing 10-30 mm CRLMs from HMs in CRC patients. The value of DL-assisted diagnosis is limited for subcentimetre CRLMs and HMs. CRITICAL RELEVANCE STATEMENT: Dynamic detection of hypoenhancing liver lesions in patients with CRC is exceptionally challenging. The DL tool we have developed can assist in evaluating CRLMs and HMs. KEY POINTS: TotalSegmentator can perform automatic segmentation of CRLMs and HMs, but demonstrates poorer segmentation consistency for subcentimeter lesions. This DL model assists radiologists in distinguishing 10-30 mm CRLMs from HMs in CRC patients. Subcentimeter CRLMs and HMs can require further MRI scanning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.